Quest Diagnostics is outperforming the growth framework it set at its prior investor day, with revenue up about 12% and earnings up just above 10% in 2025, according to CEO and President Jim Davis. The company had previously targeted 4% to 5% revenue growth, including 1% to 2% from acquisitions, and 7% to 9% earnings-per-share growth. For 2026, Quest has guided for revenue growth of nearly 8% and earnings growth of more than 13%, approaching 14%. Davis said the outperformance was driven largely by organic growth, consumer-health demand and partnerships rather than a heavier-than-expected pace of acquisitions, and noted that Quest has deployed $2.8 billion of capital in M&A since 2024, above the $1.5 billion it initially contemplated. Quest's consumer-health business, which includes its QuestHealth.com direct-to-consumer operations and partnerships with Function Health, Junction Health, Hims & Hers, Hone Health, WHOOP, Oura and Apple Health, was a $250 million business at the end of 2025 and is expected to grow at least 30% in 2026. Davis also flagged uncertainty from potential PAMA reimbursement cuts, estimating worst-case exposure at somewhat more than $100 million if every affected test rate fell by the maximum 15%.
Quest Diagnostics Incorporated
Myriad Genetics Inc
Hims Hers Health Inc